Targeting Molecular Mechanisms in Patients with Metastatic Breast Cancer: Inhibiting Estrogen Receptor-Induced Proliferation
Curriculum:
Targeting Molecular Mechanisms in Patients with Metastatic Breast Cancer: Inhibiting Estrogen Receptor-Induced Profileration
Targeting Molecular Mechanisms in Patients with Metastatic Breast Cancer: Inhibiting Estrogen Receptor-Induced Profileration
Credits:
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 28, 2017
December 28, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
This CME initiative is designed to meet the educational needs of medical oncologists, surgeons, ONS nurses, and other healthcare providers involved in the treatment of patients with breast cancer.
Relevant Terms:
Breast Cancer
Joyce O'Shaughnessy, MD
Joyce O'Shaughnessy, MD
Medical Oncologist
Texas Oncology
Baylor Charles A Sammons Cancer
Dallas, TX
Bio
Joyce A. O'Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O'Shaughnessy focuses on her practice and clinical research on breast-cancer treatment. She is Director of Breast Cancer Research and at Baylor-Sammons Cancer Center and chair of Breast Cancer Research for The US Oncology Network. Dr. O'Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995.
| 1. | Review the cellular pathways that influence estrogen-receptor activity and resultant breast-cancer pathogenesis; | 2. | Discuss the mechanisms of action of CDK 4/6 inhibitors and the resultant anti-tumorigenic effects in hormone-positive breast cancer; |
| 3. | Assess the clinical trial data for both approved and investigational CDK 4/6 inhibitors for patients with HR+, HER2 negative advanced or metastatic breast cancer. |
| 1. | Review the cellular pathways that influence estrogen-receptor activity and resultant breast-cancer pathogenesis; |
| 2. | Discuss the mechanisms of action of CDK 4/6 inhibitors and the resultant anti-tumorigenic effects in hormone-positive breast cancer; |
| 3. | Assess the clinical trial data for both approved and investigational CDK 4/6 inhibitors for patients with HR+, HER2 negative advanced or metastatic breast cancer. |
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
UMA/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA. Complete Conference Management will provide this educational activity for 1.0 contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Joyce O’Shaughnessy, MD, has provided consulting services to Novartis, AstraZeneca, Pfizer, and Celgene.
Joyce O’Shaughnessy, MD, has provided consulting services to Novartis, AstraZeneca, Pfizer, and Celgene.
CME content review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer, and the reviewer of this activity has nothing to disclose.
The content of this activity was peer reviewed by a nurse reviewer, and the reviewer of this activity has nothing to disclose.
Planning Committee
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Nina Oshiokpekhai, MS, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Nina Oshiokpekhai, MS, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
TO OBTAIN CME CREDITS:
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score 70% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
Copyright © 2017 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grant by Lilly.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
